GSK plc received US FDA approval on December 11, 2025, for Blujepa (gepotidacin), a new oral antibiotic treatment for uncomplicated urogenital gonorrhoea, providing a vital alternative for patients who cannot use current injectable therapies. This approval marks the first new class of antibiotics for gonorrhoea in over 30 years, addressing a significant public health need with over 600,000 reported cases in the US in 2023.